Table 3 Baseline characteristics of the pooled study population by status of bacterial infection ^a

N

84

77

Age (years), mean (±SD)

43.9 (18.6)

47.6 (18.8)

Gender, male

48 (57%)

39 (51%)

Hospital-acquired

12 (14%)

18 (23%)

Antibiotics given before ICU^b

30 (39%)

25 (36%)

Immune-compromising disorder

10 (12%)

11 (14%)

H1N1 status

84 (100%)

40 (52%)^d

In-hospital mortality

17 (20.2%)

15 (19.5%)

Predicted high risk^b

34 (41.0%)

49 (67.1%)^d

Mechanical ventilation

54 (64.3%)

57 (74.0%)

Vasopressor therapy^b

32 (48.5%)

34 (53.1%)

ECMO

10 (11.9%)

8 (10.4%)

Renal replacement therapy^b

10 (13.3%)

16 (22.9%)

Procalcitonin (μg/L), median (IQR)

0.56 (0.18 to 3.3)

6.2 (0.9 to 30)^d

C-reactive protein (mg/L) (median (IQR)^c

108 (50 to 213)

214 (81 to 335)^d